News/ News/ R&D

Amgen eyes swift move to ph3 for cardiovascular drug olpasiran

, , , , , , , , , 0 Comment

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible